TareBio
ActiveVaccines for any cancer or infection in weeks.
About
Our platform develops personalized or population-level vaccines for any disease in weeks by changing only one input: the immune imprint. Instead of trying to predict which antigens might work, we read out immune cells already fighting the disease in the body and reverse-engineer antigens that activate them. We've already run our platform end-to-end and created a vaccine that cured cancer in mice.
Founders
Eta Atolia· Founder/CEOFounder & CEO, TareBio (YC S26). MD-PhD from UCLA-Caltech, where she built a novel platform that develops vaccines for any cancer or infection in weeks, funded by the Gates Foundation. BS in Biology from MIT. Conducted research at the Koch Institute, Harvard Medical School, and the Weizmann. Select Awards: UCLA MD-PhD Merit Scholar, UCLA TDG Senior Fellow, MIT iGEM Gold Medal, MIT IDEAs winner, MIT Dean Advisory Group, WhiteHouse Science Fair, Bessie Lawrence Scholar, Intel STS Finalist
Product launches · 1 launch
We make personalized or population-level vaccines reverse-engineered from the immune system. We have already cured cancer in mice and are vaccinating our first patient within the year.
Change history · 4 recorded
- September 13, 2026
- YC partner updated08:01 PM
- Founder profile updated08:01 PM
- Launches refreshed08:01 PM
- August 2, 2026
- Pitch updated07:00 PM